India, Sept. 21 -- Biocon Biologics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo(R), for the treatment of HER2-positive breast cancer across multiple disease stages.The positive opinion follows the review of the marketing authorization application submitted by Biocon Biologics Ireland (formerly Biosimilar Collaborations Ireland), an indirect wholly-owned subsidiary of Biocon Biologics.The European Commission will now proceed with the final review of the application and issue its decision. ...